Shah, Fenil
Logsdon, Derek
Messmann, Richard A.
Fehrenbacher, Jill C.
Fishel, Melissa L.
Kelley, Mark R.
Article History
Received: 7 March 2017
Revised: 3 May 2017
Accepted: 3 May 2017
First Online: 8 June 2017
Competing interests
: Mark R. Kelley has licensed E3330 (APX3330) through Indiana University Research and Technology Corporation to Apexian Pharmaceuticals. Apexian Pharmaceuticals had neither control nor oversight of the studies or the study design, results or interpretation, or presentation of the data in this manuscript. They did not have to approve the manuscript in any way prior to its submission. The other authors declare that they have no competing financial interests.